IL6 and early-onset autosomal dominant Alzheimer disease: Chronic neuroinflammation is one of the main drivers of Alzheimer’s disease, and JQ1 treatment has reduced the expression levels of the pro-inflammatory modulators IL-6, IL-1β, and TNF-α, suggesting promise in the treatment of neurological disorders (10).